views of the acceptability of newly available cancer genetic risk assessment technologies among hospital administrators, clinicians, and at-risk individuals [D-7, Miesfeldt]; and adoption of cancer pharmacogenomic testing among oncologists [D-7, Dressler]. The introduction of novel genomic technologies like non-invasive prenatal testing [G-3], exome sequencing, whole genome sequencing, and microarrays [G-1] similarly demonstrates a diversity of perspectives between generalist and specialist clinicians, scientists, patients, advocacy groups, and insurers.
